-
-
As mandatory flu immunization policies continue to gain momentum in health care settings, egg allergy one of the classic exemptions to the vaccine is being redefined by public health officials.
-
In this issue: FDA issues multiple drug safety alerts; ARBs and cancer risk; and FDA actions.
-
As of 2006, the ongoing transmission of indigenous wild poliovirus (WPV) was limited to only four countries Afghanistan, Pakistan, India, and Nigeria.
-
Herrera and colleagues reviewed the use of Interferon-ã release assays (IGRAs) for the diagnosis of latent tuberculosis infection (LTBI). Interferon-ã is released by CD4 cells when infected with Mycobacterium tuberculosis (MTB), and IGRAs measure Interferon-ã response in blood.
-
Researchers and clinicians are achieving game-changing results that are revolutionizing HIV prevention, care and treatment, Michel Sidibé, Executive Director of the Joint United Nations Programme on HIV/AIDS (UNAIDS) said recently in Rome at the IAS 2011 conference.
-
At least one HIV physician is not waiting for a federal or foundation-based solution to her personal HIV doctor shortage problem. Instead she has tackled the problem by "growing" her own HIV clinician.
-
A landmark new CDC study dubbed TDF2 along with a separate trial released July 13, 2011 provide the first evidence that a daily oral dose of antiretroviral drugs used to treat HIV infection can reduce HIV acquisition among uninfected individuals exposed to the virus through heterosexual sex, the Centers for Disease Control & Prevention reports.
-
On May 23, 2011, the Food and Drug Administration approved telaprevir (Incivek®), an hepatitis C virus (HCV) protease inhibitor. Telaprevir is the second direct acting antiviral drug against the hepatitis C virus to be approved.
-
The global AIDS response is at "a scientific watershed" that includes both dramatic recent advances against HIV and the formidable challenge of extending the benefits to impoverished nations.